Biomarker Based Immunoassays Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Biomarker-based immunoassays are laboratory diagnostic techniques that use antibodies to detect and quantify specific proteins, peptides, hormones, or other biomarkers in biological samples such as blood, serum, and urine. These tests play a critical role in clinical diagnostics, pharmaceutical research, and personalized medicine, enabling early disease detection and targeted treatment strategies. The market forms a significant segment of the broader immunoassay industry, which was valued at approximately $35.5 billion in 2025.

• •Market valued at approximately $5.86 billion in 2025 with projected annual growth around 7%
• •Part of the broader global immunoassay market valued at roughly $35.5 billion in 2025
• •Used extensively in clinical diagnostics, drug development, and personalized medicine applications

The market is propelled by the rising global incidence of chronic diseases, particularly cancer, diabetes, and cardiovascular conditions, which increases demand for diagnostic testing and disease monitoring. Growing awareness of early disease screening programs and the shift toward personalized and precision medicine approaches are expanding the use of biomarker-based immunoassays in clinical decision-making. Additionally, technological innovations such as multiplex assays, automated analyzers, and point-of-care testing platforms are improving test accuracy, throughput, and accessibility.

• •Rising prevalence of oncology and other chronic diseases driving diagnostic demand
• •Expansion of early screening programs and personalized medicine initiatives
• •Technological advances in high-throughput, multiplex, and point-of-care immunoassay platforms

By application, oncology diagnostics represents the largest segment, with cancer biomarker testing accounting for approximately 63% of market share. Blood and serum specimens dominate the sample type category, representing over 50% of testing volumes, followed by other biological fluids. Geographically, North America holds the largest market share due to advanced healthcare infrastructure and high adoption of diagnostic technologies, while Asia-Pacific is expected to grow at the fastest pace driven by improving healthcare access and rising disease burden.

• •Oncology applications account for roughly 63% of market share in biomarker testing
• •Reagents and kits represent the dominant product segment at approximately 44% of market value
• •North America leads regionally, with Asia-Pacific showing the strongest growth trajectory

What are the recent trends and outlook?

The services segment, including assay development, clinical laboratory testing, and data analysis, is emerging as the fastest-growing market component as healthcare providers increasingly outsource complex biomarker testing. Multiplex assays that simultaneously measure multiple biomarkers are gaining traction due to their efficiency and ability to provide comprehensive disease profiles. The market is expected to continue expanding through 2030 and beyond, supported by ongoing biomarker discovery research, integration with companion diagnostics for targeted therapies, and growing adoption in emerging markets.

• •Services segment projected as fastest-growing due to increased outsourcing of specialized testing
• •Multiplex and high-throughput assays gaining prominence for comprehensive biomarker profiling
• •Long-term growth supported by biomarker R&D, companion diagnostics, and emerging market expansion